MBRX

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of cancers. Its clinical stage drug candidates include Annamycin, WP1066, WP1220, WP1732, WP1122 and WP1234. Annamycin is intended for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. WP1066 is an immune/transcription modulator (p-STAT3 inhibitor) and is intended to target a wide range of tumors, including brain tumors and pancreatic cancer. WP1220 is intended for the topical treatment of cutaneous T-cell lymphoma (CTCL). WP1732 is evaluated for the potential treatment of AML, pancreatic and other cancers. WP1122 and WP1234 are evaluated for the potential to treat brain tumors and pancreatic cancer through its ability to inhibit glycolysis. It is also engaged in development of drug candidates, including additional immune/transcription modulators, as well as metabolism/glycosylation inhibitors.